[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhumatoid-arthisis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhumatoid-arthisis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,71,100,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632675","phase-3-nicorandil-as-anti-inflammatory-in-rheumatoid-arthritis-100632675",false,"NCT07516769","Nicorandil as Anti-inflammatory in Rheumatoid Arthritis","Clinical Study Evaluating the Effect of Nicorandil as Anti-inflammatory and Immune Modulatory in Patients With Rheumatoid Arthritis","RA","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) i.e., 28 joints disease activity score (DAS-28) \\>2.6.\n* Patients receiving the conventional DMARDs\n\nExclusion Criteria:\n\n* Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.\n* Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.\n* Patients receiving oral prednisolone greater than 15mg\u002Fday.\n* Patients with hypersensitivity to study medications.\n* Patients using antioxidants.\n* Pregnant and lactating females.","ALL","18 Years","70 Years",{"count":21,"type":22},46,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.",[28],"Rhumatoid Arthisis",[28,30],"Nicorandil","RECRUITING","2026-06-16",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":35},"2024-11-01",{"date":39,"type":22},"2027-04",{"name":41,"class":42},"Tanta University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100617647","insole-optimization-for-rheumatoid-arthritis-patients-100617647","NCT07321340","Insole Optimization for Rheumatoid Arthritis Patients","Insole Optimization for Rheumatoid Arthritis Patients - INORA - (Insole Optimization for Rheumatoid Arthritis Patients)","INORA","Inclusion Criteria:\n\n* Patients with rheumatoid arthritis according to 2010 ACR\u002FEULAR criteria\n* RA at low activity level according to DAS28≤3.2\n* Patient with mechanical forefoot involvement on walking and improved by foot orthoses.\n\nExclusion Criteria:\n\n* Patients with a contraindication to a bone scan\n* Patients with neurological gait disorders that interfere with gait analysis\n* Exclude particularly protected persons:\n\n  * Pregnant women, parturients, nursing mothers;\n  * Persons deprived of liberty, hospitalized without consent, hospitalized for purposes other than research;\n  * Minors;",{"count":53,"type":22},10,[55],"NA","Rheumatoid arthritis affects 0.5% of the population, often leading to foot deformities and pain that are difficult to treat. Management is based on controlling inflammation, adapting footwear and using custom-made insoles, all of which have proven effective. The aim of this research is to build a digital model of plantar pressures based on CT scans, in order to optimize orthopedic insoles. The study will analyze the gait of patients with and without standard insoles to identify mechanical criteria correlated with pain. The ultimate aim is to design optimized insoles, validated by a new gait analysis.",[28],[59,60,61],"Insole","Rheumatoid arthritis","Feet","2026-06-04",{"date":64,"type":35},"2026-06-05",{"date":66,"type":35},"2026-06-02",{"date":68,"type":22},"2026-12",{"name":70,"class":42},"Centre Hospitalier Universitaire de Saint Etienne",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":43},"100628369","efficacy-of-a-self-management-smartphone-app-to-improve-safety-skills-in-patients-with-inflammatory-arthritis-100628369","NCT07460739","Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis","Efficacy of a Self-Management Smartphone App in Promoting Safety Skills of Patients With Inflammatory Arthritis Treated by Anti-Rheumatic Drugs","RHUMATOSMART","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Diagnosis of rheumatoid arthritis (RA) according to the 2010 ACR\u002FEULAR classification criteria of the American College of Rheumatology, or axial or peripheral spondyloarthritis (SpA) according to the 2009 ASAS criteria of the Assessment of SpondyloArthritis International Society, or psoriatic arthritis according to the 2009 CASPAR criteria.\n* Undergoing a treatment change to a tDMARD (biologic or JAK inhibitor) available in the SFR application.\n* No therapeutic education on tDMARDs in the past two years.\n* Ability to use a smartphone application.\n* Ability to use a website.\n* Ability to complete a questionnaire.\n* Signed informed consent for the study.\n* Covered by social security or entitled to social protection.\n\nExclusion Criteria:\n\n* Any condition that may affect comprehension or treatment adherence (chronic alcoholism, language barrier, severe psychiatric disorders, cognitive impairment).\n* Planned treatment with intravenous bDMARDs in the upcoming year.\n* Patients who have already downloaded self-management applications for their rheumatic disease.\n* Patients enrolled in a therapeutic education program: face-to-face education by a nurse or healthcare professional, or group education.\n* Patients who have already received therapeutic education on targeted DMARDs in the past two years: face-to-face education by a nurse or healthcare professional, or group education.\n* Participation in another interventional clinical trial\n* Pregnant or breast-feeding woman\n* Individual under legal protection (tutorship or guardianship) or deprived of freedom","75 Years",{"count":81,"type":22},144,[55],"Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life. Disease-modifying antirheumatic drugs (DMARDs) are used to control disease activity, reduce functional disability, and improve prognosis. These include conventional DMARDs such as methotrexate, as well as targeted DMARDs (tDMARDs), i.e., biological agents (bDMARDs) like anti-TNF alpha and JAK inhibitors. Patients treated with tDMARDs face a risk of adverse effects, including an increased risk of infections. Therapeutic patient education has been shown to help patients develop safety skills, but its effectiveness is only short-term.\n\nMobile health applications are increasingly used by patients to manage their health.\n\nThe French Society of Rheumatology (SFR) has developed a smartphone self-management application aimed at supporting people with inflammatory arthritis in managing their treatments, symptoms, and information needs. It provides advice on lifestyle and daily living, promotes treatment adherence, and enables self-assessment of disease status. The app includes seven features: a safety checklist before treatment administration, daily life aids based on French academic recommendations, treatment reminders, self-assessment of overall well-being, disease monitoring (pain, fatigue, patient global assessment of disease activity), periodic advisory messages, and a diary.\n\nThe application is not a medical device; collected data are stored on the user's smartphone. Patient data are not directly shared with physicians. Patients can use the app during consultations or share screenshots with their doctors. The app is more widely used and has a longer lifespan than most available apps, but its impact on patients still needs evaluation in a randomized controlled trial.\n\nThe primary hypothesis of the study is that using the app will improve safety skills in patients with inflammatory arthritis treated with tDMARDs compared to usual care, including access to the SFR patient information website.\n\nThe secondary hypothesis is that using the app will improve patient adherence and the patient-rheumatologist relationship.\n\nObjectives : To determine whether the mobile application improves patients' ability to acquire safety-related skills in the daily use of targeted disease-modifying antirheumatic drugs (tDMARDs), compared to usual care, including access to an informational website for patients.\n\nThe primary outcome will be the change in the BioSecure questionnaire score at 6 months after inclusion, comparing the group using the mobile application with the group using the informational website.",[28,85,86],"Spondyloarthritis (SA)","Psoriatic Arthritis (PsA)",[28,88,89,90],"spondyloarthritis","Psoriatic Arthritis","Mobile Application","NOT_YET_RECRUITING","2026-03-11",{"date":94,"type":35},"2026-03-13",{"date":96,"type":22},"2026-03",{"date":39,"type":22},{"name":99,"class":42},"Assistance Publique - Hôpitaux de Paris",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100629045","effects-of-an-aerobic-exercise-program-on-cardiovascular-risk-in-patients-with-chronic-kidney-disease-or-rheumatoid-arthritis-100629045","NCT07469540","Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis","PARCA","Inclusion Criteria:\n\n* Diagnosis of Chronic Kidney Disease (CKD) or Rheumatoid Arthritis (RA), with no other risk factors related to the disease.\n* Having a glomerular filtration rate between 45 and 20 ml\u002Fmin\u002F1.73 m², corresponding to stages III and IV not on dialysis for patients with CKD ; or have a DAS 28 score ≥ 2.6 points for patients with RA.\n* Have a medical certificate stating that there are no adverse reactions to physical activity.\n* Affiliation with a French social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* Unstabilised corticosteroid therapy and\u002For \\>10mg prednisone\u002Fday\n* Uncontrolled high blood pressure\n* Pregnant women\n* Impaired higher functions making it impossible to understand and adhere to an aerobic exercise program\n* Inability to perform physical exercise, regardless of the cause (neurological, central or peripheral, cardiovascular or respiratory, or musculoskeletal)\n* Legal incapacity or limited legal capacity\n* Subject unlikely to cooperate with the study and\u002For low cooperation anticipated by the investigator\n* Subject without health insurance\n* Subject is in the exclusion period of another study involving human subjects that may interfere with the results of this study, particularly by affecting inflammatory status and the cardiovascular system.","50 Years",{"count":109,"type":22},90,[55],"The goal of this clinical trial is to determine whether an aerobic exercise program can reduce cardiovascular risk in patients with systemic inflammation, such as those with rheumatoid arthritis and chronic kidney disease.\n\nThe main questions this study aims to address are:\n\n* Does an individualized aerobic exercise program reduce cardiovascular risk, as assessed arterial stiffness and endothelial function ?\n* What are the effects of this exercise program on inflammation and immunosenescence?\n\nResearchers will compare an individualized aerobic exercise program with a therapeutic education program (consisting of educational phone calls only) and a control group with no intervention.\n\nParticipants will:\n\n* Perform three physical activity sessions per week for six weeks (45-minute sessions at 60-80% of heart rate reserve);\n* Attend clinic visits at baseline, after the 6-week intervention, and at a 6-week follow-up after the intervention;\n* Undergo assessments including pulse wave velocity, hyperemic reactivity, and blood analyses.",[113,28,114,115],"Aerobic Exercise","Chronic Kidney Disease","Cardiovascular (CV) Risk",[117,118,119,120],"Systemic Inflammation","Arterial Stiffness","Hyperemic reactivity","Blood analyses","2026-03-10",{"date":94,"type":35},{"date":124,"type":22},"2026-03-16",{"date":126,"type":22},"2026-12-31",{"name":128,"class":42},"Jérôme Bouchan",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100568924","phase-4-jak-inhibitor-dose-tapering-strategy-study-100568924","NCT06687551","JAK Inhibitor Dose TAPering Strategy Study","JAK Inhibitor Dose TAPering Strategy Study in Low Disease Activity Rheumatoid Arthritis Patients","JAK-TAP","The inclusion criteria will be\n\n1. Aged ≥ 18 years at baseline.\n2. Rheumatoid arthritis defined by the ACR\u002FEULAR criteria.\n3. Treated with a JAK inhibitor, full dose for at least 6 months.\n4. The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion.\n5. Being in LDA (CDAI≤10) for at least 6 months.\n6. With a CRP level below the laboratory standard within the month before the inclusion visit.\n7. Women of childbearing potential (WCBP) must have a negative pregnancy test before starting study\n\nThe non-inclusion criteria will be:\n\n1. Concomitant disease needing to be treated by the JAK inhibitor at full-dose (for example inflammatory bowel disease).\n2. Patient with a history of JAK-inhibitor dose reduction\u002Fspacing before enrollment in the study with the JAK-inhibitor currently being taken.\n3. Evidence of flare-up within the last 6 months prior to the inclusion.\n4. Patient who received glucocorticoids \\> 5mg\u002Fday in the 3 months prior the inclusion because of the disease activity of the RA.\n5. Patient requiring corticoid joint injections in the 3 months prior to inclusion or with scheduled joint injections, to control disease activity.\n6. Patient at risk for complication according to the ANSM (60) (current or past smokers, patients at risk of VTE, cancer or major cardiovascular problems, aged ≥ 65 years) at baseline AND currently taking baricitinib or filgotinib.\n7. Patient taking associated bDMARD (including anti-TNF, anti-IL6, anti-CD20, abatacept, anti-IL17, anti-IL12\u002F23, anti-IL23, anti-IL1, anti-BAFF, anti-IL5 pathways).\n8. Patient taking immunotherapy for neoplasia.\n9. Surgery scheduled in the next 12 months.\n10. Fibromyalgia according to the physician's opinion.\n11. Anticipated poor compliance with the strategy.\n12. Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation.\n13. Alcohol and\u002For drug misuse as determined by the investigator.\n14. Pregnancy or breastfeeding.\n15. Non-affiliation to the French Social Security System.\n16. Patient unwilling to sign the informed consent form.\n17. Patient under legal protection.","65 Years",{"count":139,"type":22},308,[141],"PHASE4","This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose.\n\nParticipants will:\n\n* Either take\n\n  1. JAK inhibitor dose-tapering strategy.\n  2. JAK inhibitor continuous therapy strategy.\n* Visit the clinic once every 3 months for checkups and tests\n* Keep a diary of their treatment intake and symptoms",[28],[145,146,60],"JAK-inhibitor","dose reduction","2024-11-12",{"date":149,"type":35},"2024-11-13",{"date":151,"type":22},"2025-01-01",{"date":153,"type":22},"2029-04-01",{"name":155,"class":42},"University Hospital, Toulouse"]